Psychedelics to
Therapeutics

Psychedelics to Therapeutics

Latest Updates

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
Cybin and Kernel Announce Results from Kernel Flow®
Piloting of Feasibility Study Measuring Psychedelic Effects on the Brain
What We do

We’re on a mission to revolutionize mental healthcare.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.

The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Sign up to receive news and updates.
What We do

We’re on a mission to revolutionize mental healthcare.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.

The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Sign up to receive news and updates.

Led by Science

Cybin is engineering next generation psychedelic molecules. We are transforming the mental health treatment landscape by combining novel psychedelic molecules with controllable drug delivery systems through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.

Novel Second-Generation Psychedelics based on well-known scaffolds including Psilocybin, DMT, MDMA with improved bioavailability.

Leveraging cutting-edge Neuroimaging technology to generate quantitative data to better understand psychedelic therapies.

Developing ground-breaking psychotherapy that integrates leading clinical approaches to promote supportive healing with psychedelic medicine.

1

3 active drug programs targeting Major Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005).

1

189 pre-clinical studies completed and progressing lead programs toward FDA IND filings.

> 1

>50 novel compounds developed with more than 15 patents pending across 6 patent families. 

Backed by an
Experienced Team

300+ combined peer reviewed publications by scientific leadership that includes work in addiction and psychedelics, oversight of 60+ IND programs with the FDA as well as success in helping develop multiple widely used drugs.

Successfully helped develop and bring to market over 5 widely-used commercially available prescription drugs.

NEO:CYBN $1.09 CAD 0.01 0.926% view stock »
NYSE:CYBN $0.8566 USD 0.0066 0.776% view stock »

In the Press